医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Litigation Judgment Removes A Major Hurdle For Esomeprazole Strontium Delayed-Release Capsules from Hanmi and Marketing Partner Amneal

2013年06月05日 AM01:25
このエントリーをはてなブックマークに追加


 

SEOUL, Korea

Hanmi Pharmaceutical Company Limited and Amneal Pharmaceuticals, LLC announced today that, pursuant to a confidential settlement agreement, a consent judgment has been entered by the United States District Court for the District of New Jersey with respect to the ongoing patent infringement litigation between Hanmi and AstraZeneca PLC involving Hanmi’s proposal to market esomeprazole strontium delayed release capsules. AstraZeneca originally filed suit in February of 2011 alleging that Hanmi’s product infringed two AstraZeneca patents involving its heartburn drug, Nexium®.

The consent judgment provides that (1) Hanmi has acknowledged that the two asserted patents are enforceable and valid, and (2) the Hanmi product does not infringe the claims of the two asserted patents based upon the claim construction ruling issued by the District Court on December 12, 2012. Although AstraZeneca has reserved its right to appeal the District Court’s claim construction, Hanmi believes that the District Court’s claim construction ruling is sound and, accordingly, Hanmi’s non-infringement position is on solid ground.

Hanmi’s product obtained tentative FDA approval on April 30, 2013. Hanmi and its marketing partner, Amneal Pharmaceuticals LLC, anticipate receiving final FDA approval shortly. Hanmi’s product would be the first non-innovator pharmaceutical product commercialized in the United States that contains the active moiety esomeprazole. Hanmi would also be the first Korean company to enter the United States market under the Hatch-Waxman statutory framework.

CONTACT

Media Relations contact:
Cheryl Lechok Communications, LLC
Cheryl
Lechok, +1 203-613-1506
clechok@optonline.net

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Morinaga Milk Study Suggests Infant-Type Human-Residential Bifidobacteria May Benefit Infant Health by Improving Digestion of Peptides in Milk and Grains
  • CANbridge Pharmaceutical and WuXi Biologics Enter into Strategic Partnership for Rare Disease Therapeutics
  • 武田呈报3期ALTA-1L试验结果,显示在晚期ALK+非小细胞肺癌一线治疗中,ALUNBRIG® (brigatinib)的颅内有效性优于克唑替尼
  • Philip Morris International Launches Next Generation of IQOS, the World’s Leading Heated Tobacco Product
  • ポットネットワーク・ホールディングスが610万ドルを超える収益で過去最高の第3四半期を終える